The Form 4 filing, an SEC report of insider stock activity, lists November 16, 2026, as the trade date. It was filed on November 18, 2026, two days later.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 70,000 |
| Price | $27.68 |
| Total Transaction Value | $1,937,282.13 |
| Insider | |
| Ticker Symbol | ANRO |
| Company | Alto Neuroscience, Inc. |
| Insider Name | Hanley Jr. Michael Conick |
| Insider Title | CHIEF OPERATING OFFICER |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 0 |
| Position Size Change | 100.00% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of ANRO shares, reported with transaction code S. The filing covers three sale transactions by one insider.
What was the average price of the transaction?
The average sale price was $27.68 per share, rounded to the nearest cent. Separate prices for each of the three sales were not available in the transaction details provided.
How did this transaction affect the insider's holdings?
The sales reduced Michael Conick Hanley Jr.'s reported shares by 70,000, leaving zero shares in that balance. The reported 100.00% change means all shares in that balance before the sales were sold. Holdings in other accounts or securities are unknown.
What's the total transaction value?
The total value was $1,937,282.13 across the three sales, rounded to the nearest cent. That amount covers all three reported transactions.
Are there any special circumstances around this transaction?
Yes. The available filing information indicates a Rule 10b5-1 plan reference or checkbox. These plans set trading instructions in advance. No footnote text was available to confirm which of the three sales the plan covered. The plan's start date and trading schedule are unknown. The reference alone does not confirm that the trades met all of the rule's legal requirements.
For research purposes only; not investment advice.